Future Directions for Intrathecal Pain Management: A Review and Update From the Interdisciplinary Polyanalgesic Consensus Conference 2007

@article{Deer2008FutureDF,
  title={Future Directions for Intrathecal Pain Management: A Review and Update From the Interdisciplinary Polyanalgesic Consensus Conference 2007},
  author={Timothy R Deer and Elliot S. Krames and Samuel J. Hassenbusch and Allen W. Burton and David Caraway and Stuart Dupen and James C Eisenach and Michael Erdek and Eric J. Grigsby and Phillip Kim and Robert Levy and Gladstone C. McDowell and Nagy Mekhail and Sunil J. Panchal and Joshua P. Prager and Richard L. Rauck and Michael F. Saulino and Todd B. Sitzman and Peter S Staats and Michael Stanton‐Hicks and Lisa Jo Stearns and K Dean Willis and William O. Witt and Kenneth A. Follett and Marc Huntoon and Leong Liem and James P. Rathmell and Mark S Wallace and Eric E. Buchser and Michael Cousins and Ann Ver Donck},
  journal={Neuromodulation: Technology at the Neural Interface},
  year={2008},
  volume={11}
}
Background.  Expert panels of physicians and nonphysicians, all expert in intrathecal (IT) therapies, convened in the years 2000 and 2003 to make recommendations for the rational use of IT analgesics, based on the preclinical and clinical literature known up to those times, presentations of the expert panels, discussions on current practice and standards, and the result of surveys of physicians using IT agents. An expert panel of physicians and nonphysicians has convened in 2007 to update… 
View on Wiley
californiapainmedicinecenter.com
28 Citations
Background Citations
4

28 Citations

Intrathecal Drug Delivery: Innovation

This chapter will present a brief history of intrathecal (IT) therapy, discuss the current state of the technology, and finally discuss future directions.

Practice Choices in Targeted Intrathecal Drug Delivery: An Online Survey Conducted by the Polyanalgesic Consensus Committee

Intrathecal drug delivery (IDD) has evolved over the past 40 years to treat intractable pain and spasticity not successfully managed with other treatment modalities or routes of drug delivery. The…

Current Developments in Intraspinal Agents for Cancer and Noncancer Pain

An update on newly approved as well as emerging IT agents and the advances in technology for their delivery is provided.

Intrathecal drug delivery for chronic pain management-scope, limitations and future

The main indications, pre-implantation trials and different implantation techniques, the licensing of drugs for intrathecal use and the adverse effects and benefits of this therapy are explored.

Polyanalgesic Consensus Conference 2012

    T. Deer
    Medicine
    Neuromodulation : journal of the International Neuromodulation Society
  • 2012
This body of work chaired by myself, Robert Levy, MD, PhD, and Joshua Prager,MD, is ambitious in giving the most comprehensive and detailed guidance in the history of Intrathecal Drug Delivery Systems (IDDS).

Multimodal Pain Management in the Perioperative Setting

An accounting of the available opioid and non-opioid pharmacologic agents, regional analgesia techniques, and complementary modalities that may be considered for optimal pain relief in the perioperative setting is presented.

Intrathecal midazolam as supplementary analgesia for chronic lumbar pain--15 years' experience.

Intrathecal midazolam is a useful supplement to standard analgesic therapy with opioids, non-opioids, or spinal steroids in patients with chronic low back pain and failed back surgery syndrome after a single-shot intrathecal administration.

History and Present State of Targeted Intrathecal Drug Delivery

The historical antecedents, present state, and emerging future of the neuromodulatory technique of targeted intrathecal drug delivery (TIDD) for chronic pain is emphasized.

Practice choices and challenges in the current intrathecal therapy environment: an online survey.

Intrathecal pain management practices continue to evolve as the options for treatment increase, and the body of applicable scientific literature grows; however, economic considerations can influence clinical decisions and may interfere with treatment choice and patient access to therapy.

Intrathecal drug delivery for chronic non-malignant pain : pharmacological complications, cost effectiveness and long-term outcomes

Despite potential side effects, this therapy can be effective over periods longer than 10 years in appropriately selected patients and the cost effectiveness of IDD systems was confirmed based on real patients’ data.

39 References

Management of Intrathecal Catheter‐Tip Inflammatory Masses: An Updated 2007 Consensus Statement From An Expert Panel

    T. DeerElliot S. Krames Ann Ver Donck
    Medicine
    Neuromodulation : journal of the International Neuromodulation Society
  • 2008
An expert panel of physicians and nonphysicians convened in 2007 to review previous recommendations and to form recommendations for the rational use of IT agents as they pertain to new scientific and clinical information regarding the etiology, prevention and treatment for IT granuloma.

Polyanalgesic Consensus Conference 2007: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert Panel

    T. DeerElliot S. Krames Ann Ver Donck
    Medicine
    Neuromodulation : journal of the International Neuromodulation Society
  • 2007
An expert panel of physicians convened in 2007 to update previous recommendations and to form guidelines for the rational use of intrathecal opioid and nonopioid agents.

Clinical guidelines for intraspinal infusion: report of an expert panel. PolyAnalgesic Consensus Conference 2000.

Current practices in intraspinal therapy--a survey of clinical trends and decision making.

Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery-- report of an expert panel.

Future directions in the management of pain by intraspinal drug delivery.

Intrathecal octreotide for relief of intractable nonmalignant pain: 5-year experience with two cases.

This article describes the 5-year clinical course of two patients receiving intrathecal octreotide for severe, intractable nonmalignant pain and the results of blinded, randomized "N of 1" trials conducted in each patient.

The Use of Continuous Intrathecal Infusion of Octreotide in Patients with Chronic Pain of Noncancer Origin: An Evaluation of Side‐effects and Toxicity in a Prospective Double‐blind Fashion

This study examined the safety of intrathecal octreotide in noncancer pain using continuous intr Athecal infusion to show whether the drug should be considered an alternative to opioids in chronic infusion for pain.

Efficacy of intrathecal adenosine for postoperative pain relief

Intrathecal adenosine 1000 μg is not effective as an analgesic for postoperative pain relief, and there is no pre‐emptive effect.

Phase I Safety Assessment of Intrathecal Injection of an American Formulation of Adenosine in Humans

Data from a phase I safety trial of intrathecal injection of the American formulation of adenosine, which lacks mannitol, suggest that this agent does not produce a high incidence of severe side effects and is suitable for analgesia in humans.